RxDoctor Payments Data

Mohamed Morsy, MD

Cardiovascular Disease · Charlottesville, VANPI 1902865157

Payments from drug & device makers

$13,823in general payments, 2019–2025

Across 53 payments — averaging $260.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Novartis$5K
  • Edwards Lifesciences$3K
  • Cardiac Dimensions, Inc.$246
  • Penumbra, Inc.$163
  • Medtronic$153
  • plus $466 from 6 others

What the payments were for

  • Speaking & faculty fees$2,37527%
  • Travel & lodging$4,74354%
  • Food & beverage$1,51117%
  • Education$991%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott24$5,131
Novartis1$5,095
Edwards Lifesciences12$2,569
Cardiac Dimensions, Inc.1$246
Penumbra, Inc.1$163
Medtronic(2 entities)4$153
Cordis US CORP.1$116
AstraZeneca1$99
Irhythm Technologies, Inc.1$94
Amgen4$65
Johnson & Johnson1$62
Boehringer Ingelheim2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,823 in reported general payments places this provider in the 80th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$87,923
Medicare patients
1,382
Services billed
1,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$82,438
FarxigaDapagliflozin Propanediol75$72,031
Repatha SureclickEvolocumab12$16,370
JardianceEmpagliflozin12$13,091
BrilintaTicagrelor13$6,782
Metoprolol Succinate147$1,675
Rosuvastatin Calcium91$1,208
Atorvastatin Calcium134$1,059
Ezetimibe63$871
Midodrine Hcl12$681
Losartan Potassium59$579
Amlodipine Besylate129$579
Lisinopril108$560
Bumetanide12$507
Carvedilol49$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$99$78,81388 claims
Boehringer IngelheimJardiance$31$13,09112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →